• Should time in range replace HbA1c as the primary outcome metric for diabetes?

    3 days ago - By Healio

    If you're talking about patient management, there is no question about the value of CGM and time in range, because HbA1c is really not worth anything for management.
    HbA1c is not actionable. There's nothing that HbA1c will tell you that will help the patient or the physician to change treatment in a specific way. CGM has completely changed that, because you are now able to analyze relationships and trends and focus on whether you should be maximizing time range, minimizing time below range or trying to reduce glycemic variability.
    CGM is not just a way to record glycemic status, but
    Read more ...

     

  • Use of CGM metrics more common in diabetes care, but still limited

    Use of CGM metrics more common in diabetes care, but still limited

    3 days ago - By Healio

    With uptake of diabetes devices continuing to expand, more providers are shifting away from looking solely at HbA1c and toward analyzing continuous glucose monitoring data.
    People with diabetes using wearable CGM are able to share device-generated ambulatory glucose profiles with physicians and other care providers. These 14-day reports calculate the amount of time a user spends within a glucose target range of 70 mg/dL to 180 mg/dL. The report also includes the time spent in hypoglycemia or hyperglycemia, a user's mean glucose level, glucose variability and a glucose management
    Read more ...